Divi's Laboratories Limited (NSE:DIVISLAB)

Market Cap	1.76T
Revenue (ttm)	93.60B
Net Income (ttm)	21.91B
Shares Out	265.47M
EPS (ttm)	82.53
PE Ratio	80.35
Forward PE	65.37
Dividend	30.00 (0.45%)
Ex-Dividend Date	Jul 25, 2025

Volume	364,734
Average Volume	632,063
Open	6,645.00
Previous Close	6,636.00
Day's Range	6,603.00 - 6,670.50
52-Week Range	4,180.50 - 6,764.00
Beta	0.28
RSI	64.51
Earnings Date	May 23, 2025

About Divi's Laboratories

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It al...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 9,741
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: DIVISLAB

Financial Performance

In 2024, Divi's Laboratories's revenue was 93.60 billion, an increase of 19.31% compared to the previous year's 78.45 billion. Earnings were 21.91 billion, an increase of 36.94%.